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Abstract. The purpose of the study was to assess the efficacy of single photon emission 
computed tomography (SPECT) with 
199
Tl and 
99m
Tc-MIBI in the detection of breast, laryngeal 
and hypopharyngeal cancers. Materials and Methods: a total of 220 patients were included into 
the study. Of them, there were 120 patients with breast lesions (100 patients with breast cancer 
and 20 patients with benign breast tumors) and 100 patients with laryngeal/hypopharyngeal 
diseases (80 patients with laryngeal/hypopharyngeal cancer and 20 patients with benign 
laryngeal/hypopharyngeal lesions). Results: no abnormal 
199
Tl uptake was seen in all patients 
with benign breast and laryngeal lesions, indicating a 100% specificity of 
199
Tl SPECT. In 
breast cancer patients, increased 
199
Tl uptake in the breast was visualized in 94.8% patients, 
99m
Tc-MIBI in 93.4% patients. Increased 
199
Tl uptake in axillary lymph nodes was detected in 
60% patients and 
99m
Tc-MIBI in 93.1% patients. In patients with laryngeal/hypopharyngeal 
cancer, sensitivity of SPECT with 
199
Tl and 
99m
Tc-MIBI were 95%. The 
199
Tl SPECT 
sensitivity in identification of regional lymph node metastases in patients with 
laryngeal/hypopharyngeal cancer was 75% and the 
99m
Tc-MIBI SPECT sensitivity was 17%. 
Conclusion: the data obtained show that SPECT with 
199
Tl and 
99m
Tc-MIBI can be used as one 
of the additional imaging methods in detection of tumors. 
1. Introduction 
According to recent WHO data, more than 10 million newly diagnosed cancer cases occur annually in 
the world. In many countries, cancer ranks the second most common cause of death following 
cardiovascular diseases [1]. 
Nuclear medicine techniques have the advantage over X-ray or magnetic resonance imaging in 
terms of higher specificity with a similar high sensitivity for cancer detection [2, 3 ,4]. Moreover, the 
use of nuclear medicine imaging in detection of laryngeal/hypopharyngeal tumors allows prevention 
of unnecessary diagnostic invasive procedures. 
99mTс-methoxy-isobutyl-isonitrile (99mTc-MIBI) is the most widely used single photon emission 
computed tomography (SPECT) tracer in detecting malignant disease [5, 6[6]]. However, this tracer 
with a relatively high sensitivity has a rather low specificity. Therefore, the search for 
radiopharmaceuticals characterized by a high specificity while maintaining adequate sensitivity is of 
great importance. 
More than 30 years ago, the diagnostic value of 
201
Tl for detecting malignant tumors was studied. It 
was shown that 
201
Tl, a biological potassium analogue, actively accumulated in tumors [6[6]]. Findings 
from animal studies demonstrated that 
201
Tl had higher tumor accumulation compared to other 
radiopharmaceuticals [8, 9[9]]. However, a long half-life (72 hours) of 
201
Tl limited its widespread use, 
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since there was a risk of increased radiation dose to the patient’s body and critical organs, especially 
during re-examinations, for example during chemotherapy. 
It is proposed that 
199
Tl is a more promising isotope than 
201
Tl, which is currently used in nuclear 
medicine. Unlike 
201
Tl, 
199
Tl has a more simple and cheaper production method. There are many 
reports on the use of this isotope for myocardial perfusion scintigraphy. Cellular uptake mechanism of 
199
Tl is the same as that of 
201
Tl. However, because of its short half-life (7.4 hours), radiation dose to 
the patient’s whole body and critical organs is significantly reduced. By using 199Тl, the radiation dose 
to critical organs is 4-15 times lower than that by using 
201
Tl. It allows 
199Тl scintigraphy to be 
performed 5 times a year for the same patient [10, 11, 12]. 
The aim of our study was to evaluate the efficacy of SPECT with 
199Тl in the detection of breast 
and laryngeal/hypopharyngeal carcinomas. 
2. Experiment 
A total of 220 patients were included into the study. There were 120 women with breast disease. Out 
of them, 39 patients with stage T1-4N0-2M0 breast cancer and 20 patients with benign breast lesions 
were injected with 
199
Tl, and 61 patients with stage T1-4N0-2M0 breast cancer were injected with 
99m
Tc-
MIBI. There were 80 patients with stage T1-3N0-2M0 laryngeal and hypopharyngeal cancers (including 
20 patients with recurrent laryngeal/hypopharyngeal cancer) and 20 patients with benign diseases, 
among them, 50 patients were injected with 
199
Tl and the other 50 patients were injected with 
99m
Tc-
MIBI. None of the patients at the time of the survey showed evidence of distant metastasis. 
Besides conventional imaging methods such as computed tomography, ultrasound, 
fibrolaryngoscopy and biopsy, all patients underwent preoperative SPECT with 
199Тl or 99mTc-MIBI. 
The patients were subsequently operated on and surgical specimens were examined histologically and 
immunohistochemically. Patients with benign breast lesions underwent sectoral resection of the breast 
with subsequent histological examination. 
Single photon emission computed tomography was performed using a double-head gamma-camera 
(E.CAM 180, Siemens) equipped with parallel high energy collimators for 
199Тl and parallel low 
energy collimators for 
99m
Tc-MIBI. The injection of 
199Тl at the dose of 260 MBq or 99mTc-MIBI at the 
dose of 740 MBq was made intravenously. In patients with breast disease, injection was made into the 
antecubital vein contralaterally to the breast lesion or in the pedal vein. Images of the breast were 
obtained with the patients lying in the supine position with the arms raised over the head and with the 
chest, both breasts, axilla and the myocardium, included into the field of view. For obtaining SPECT 
images in patients with laryngeal/hypopharyngeal cancer, patients were also placed in a supine 
position, and the detector’s field of the view encompassed the head and neck region and trachea to the 
bifurcation. A total of 32 projection images were recorded into a 64×64 matrix (30 seconds per 
projection), without magnification factor. The scan images were analyzed using the manufacturer 
software (e.soft, Siemens, Germany). Three-dimensional images of the chest, sagittal, transverse and 
coronal sections were obtained. Single photon emission computed tomography scans were visually 
assessed. Images of contralateral areas were compared and asymmetrically increased radiotracer 
uptake was considered pathological. 
3. Results and discussion 
Single photon emission computed tomography revealed no abnormal 
199
Tl uptake in the chest wall and 
breasts of patients with benign breast lesions. Despite a small group of patients (n=20), the specificity 
of SPECT with 
199
Tl was 100%. 
In breast cancer patients, the increased 
199
Tl uptake was visualized in 37 (94.8%) of the 39 patients, 
of the 6 patients with tumors less than 10 mm, 4 showed abnormal radiotracer uptake (Figure 1). In 
one case, a large mass detected by mammography and ultrasound appeared as a cluster of 
microcalcifications. Carrying out of SPECT with 
99m
Tc-MIBI revealed abnormal formations in the 
projection of the mammary glands in 59 (93.4%) out of 61 patients (Figure 2). Tumors greater than 
10 mm were detected by 
199
Tl and 
99m
Tc-MIBI SPECT in 100% of cases. 
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Figure 1. SPECT with 
199
Tl for the patient with stage T2N0M0 cancer in the left breast. 
 
Figure 2. SPECT with 
99m
Tc-MIBI for the patient with stage T1N0M0 cancer in the left breast. 
 
It is well known that secondary infiltrative ductal breast carcinoma can be difficult to diagnose. In 
our study, the accuracy in differentiating malignant from benign breast lesions by SPECT with 
199
Tl 
was 100%, as well as with 
99m
Tc-MIBI (Figures 3,4). Identification of multicentric breast cancer is an 
important factor in diagnosis of breast cancer. In our study, multicentric breast cancer was diagnosed 
in 66.6% patients during the study with 
199
Tl and in 46.1% with 
99m
Tc-MIBI (Figures 5,6). 
 
 
Figure 3. SPECT with 
199
Tl for the patient with secondary infiltrative ductal breast carcinoma in the 
right breast. 
 
Figure 4. SPECT with 
99m
Tc-MIBI for the patient with secondary infiltrative ductal breast carcinoma 
in the right breast. 
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Figure 5. SPECT with 
199
Tl for the patient with multicentric breast cancer in the right breast. 
 
Figure 6. SPECT with 
99m
Tc-MIBI for the patient with multicentric breast cancer in the right breast. 
 
As regard to lymph node involvement, increased 
199
Tl uptake in the axillary lymph nodes was 
observed in 15 of the 25 patients (60%) with histologically verified metastases (Figure 7). Only 2 of 
the 5 patients had abnormal radiotracer uptake in the pectoral and subclavicular lymph nodes 
(Figure 8). Thus, the 
199
Tl SPECT sensitivity for the detection of metastatic regional lymph nodes in 
breast cancer patients was 60%. 
 
 
Figure 7. SPECT with 
199
Tl in the patient with stage T2N1M0 cancer in the left breast. Axillary lymph 
node visualization. 
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Figure 8. SPECT with 
199
Tl in the patient with stage T2N3M0 cancer in the right breast. Visualization 
of pectoral and subclavicular lymph nodes. 
 
It was possible to visualize the modified axillary lymph nodes in almost all cases during the study 
with 
99m
Tc-MIBI: in 27 (93.1 %) out of 29 patients with verified metastasis pathological inclusion of 
the 
99m
Tc-MIBI in axillary region was detected (Figure 9). In addition, pathological changes in the 
projection of pectoral lymph nodes, subclavian and subscapularis groups were detected in 5 patients. 
This technique allowed us to differentiate between different levels of lymph nodes (Figure 10). The 
sensitivity of the SPECT with 
99m
Tc-MIBI in identifying metastatic regional lymph nodes was 93.1 %. 
The specificity of SPECT with 
199
Tl was 100%, with 
99m
Tc-MIBI – 80%. 
 
 
Figure 9. SPECT with 
99m
Tc-MIBI in the patient with stage T2N1M0 cancer in the left breast. 
Axillary lymph node visualization. 
 
Figure 10. SPECT with 
99m
Tc-MIBI in the patient with stage T2N3M0 cancer in the right breast. 
Visualization of pectoral, subclavicular lymph nodes. 
 
In laryngeal/hypopharyngeal cancer patients, abnormal both 
199
Tl and 
99m
Tc-MIBI uptake was 
detected in 95 % patients with primary laryngeal/hypopharyngeal cancer (Figures 11, 12). It should be 
noted that despite limitations for SPECT in visualization of tumors less than 10 mm. The minimum 
lesion size was 4 mm in greatest dimension. 
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In 20 of the 20 patients with recurrent laryngeal/hypopharyngeal cancer was detected abnormal 
uptake both 
199
Tl and 
99m
Tc-MIBI, it was 100 % sensitivity of SPECT with 
199
Tl and 
99m
Tc-MIBI in the 
diagnosis of recurrent laryngeal/hypopharyngeal cancer. 
 
 
Figure 11. SPECT with
 199Тl for the patient with primary laryngeal cancer. 
 
Figure 12. SPECT with
 99m
Tc-MIBI for the patient with primary laryngeal cancer. 
 
Histological examination of specimens obtained by ultrasound-guided fine needle aspiration biopsy 
showed cervical lymph node metastases in 18.3% of cases. On SPECT the lymph nodes, affected by 
metastases, were visualized in the form of tracer hyperfixation focus of irregular shape with rough, 
indistinct boundaries, expressed by a nonuniform distribution of tracer, usually of low intensity.  
Single photon emission computed tomography with 
199
Tl could detect biopsy-proven lymph node 
metastases in 75 % of cases (Figure 13). When performing SPECT with 
99m
Tc-MIBI we were able to 
identify the accumulation of the drug in the projection of lymph nodes, affected by metastases, in 
2 (17%) of 12 patients (Figure 14). We assume, that such a low information content of SPECT with 
99m
Tc-MIBI in the detection of metastases in regional lymph nodes is primarily related to their small 
size and physiological, initially high accumulation of 
99m
Tc-MIBI in the projection of the thyroid and 
submandibular salivary glands, which often screens the zones of the regional lymph collector 
(Figure 15). This effect is less pronounced when using of 
199
Tl (Figure  16). 
 
 
Figure 13. SPECT with
 199Тl for the patient with primary laryngeal cancer and cervical lymph node 
metastases. 
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Figure 14. SPECT with
 99m
Tc-MIBI for the patient with primary laryngeal cancer and cervical lymph 
node metastases. 
 
Figure 15. Screens the zones physiological accumulation of 
99m
Tc-MIBI in the projection of the 
thyroid gland and submandibular salivary glands. 
 
Figure 16. Physiological accumulation of 
199Тl. 
4. Conclusion 
Our first experience of using 
199Тl has clearly indicated that this radiopharmaceutical represents a useful 
diagnostic tool for the detection of breast and laryngel/hypopharyngeal cancers. Single photon emission 
computed tomography with 
199Тl showed 100% specificity for detecting breast cancer, when compared to 99mTc-
MIBI with reported specificity varying from 85% to 94% [5, 13]. 
With regard to the assessment of regional lymph node metastasis in patients with laryngeal/hypopharyngeal 
cancer, 
199Тl SPECT demonstrated high specificity, whereas 99mTc- MIBI failed to evaluate the status of regional 
lymph nodes due to its physiological high uptake in the thyroid gland. 
Despite the above advantages, 
199Тl has also disadvantages. This cyclotron-produced radiopharmaceutical has 
a higher cost compared to 
99m
Tc, the most widely used radioisotope in nuclear medicine. Moreover, our findings 
have demonstrated a rather low sensitivity in the detection of regional lymph node metastases in breast cancer 
patients, thus significantly impairing the diagnostic accuracy. 
Anyway, 
199Тl is a promising radiopharmaceutical for the detection of malignant tumors, however, further 
studies are required to determine its role in the cancer diagnostic algorithm. 
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